File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Rituximab in the management of follicular lymphoma

TitleRituximab in the management of follicular lymphoma
Authors
KeywordsLymphoma, Follicular
Rituximab
Issue Date2011
PublisherHong Kong Academy of Medicine Press. The Journal's web site is located at http://www.hkjr.org
Citation
Hong Kong Journal Of Radiology, 2011, v. 14 n. 4 SUPPL., p. 63-67 How to Cite?
AbstractThe incidence of follicular lymphoma, a low-grade malignant B-cell lymphoma, is increasing in most Asian populations. Follicular lymphoma is generally considered to be indolent with a life expectancy of approximately 10 to 14 years. However, it is characterised by repeated relapse, and disease progression typically occurs 3 to 5 years after initial treatment. Rituximab, a monoclonal antibody, demonstrates consistent survival benefits when administered as part of a first- and second-line immunochemotherapy. Consequently, rituximab is now considered the standard of care for follicular lymphoma, and is recommended as the first-line therapy for early-stage asymptomatic disease. Available evidence also demonstrates survival benefits for rituximab as maintenance therapy in patients who have responded to induction therapy with either frontline rituximab or chemotherapy. Improved survivals in patients receiving rituximab-based first-line induction and maintenance therapies suggest that this treatment strategy may be preferable to adopting a watch-and-wait policy in patients with asymptomatic follicular lymphoma. While rituximab has improved treatment outcomes in follicular lymphoma patients, the appropriate timing, dosing and duration of therapy remain to be clarified in future clinical trials. Given the indolent nature of follicular lymphoma and the relatively long life expectancy associated with this disease, prognostic tools have an important role in guiding clinical decisions based on individual patient risk. © 2011 Hong Kong College of Radiologists.
Persistent Identifierhttp://hdl.handle.net/10722/163482
ISSN
2015 SCImago Journal Rankings: 0.113
References

 

DC FieldValueLanguage
dc.contributor.authorKwong, YLen_US
dc.date.accessioned2012-09-05T05:31:50Z-
dc.date.available2012-09-05T05:31:50Z-
dc.date.issued2011en_US
dc.identifier.citationHong Kong Journal Of Radiology, 2011, v. 14 n. 4 SUPPL., p. 63-67en_US
dc.identifier.issn2223-6619en_US
dc.identifier.urihttp://hdl.handle.net/10722/163482-
dc.description.abstractThe incidence of follicular lymphoma, a low-grade malignant B-cell lymphoma, is increasing in most Asian populations. Follicular lymphoma is generally considered to be indolent with a life expectancy of approximately 10 to 14 years. However, it is characterised by repeated relapse, and disease progression typically occurs 3 to 5 years after initial treatment. Rituximab, a monoclonal antibody, demonstrates consistent survival benefits when administered as part of a first- and second-line immunochemotherapy. Consequently, rituximab is now considered the standard of care for follicular lymphoma, and is recommended as the first-line therapy for early-stage asymptomatic disease. Available evidence also demonstrates survival benefits for rituximab as maintenance therapy in patients who have responded to induction therapy with either frontline rituximab or chemotherapy. Improved survivals in patients receiving rituximab-based first-line induction and maintenance therapies suggest that this treatment strategy may be preferable to adopting a watch-and-wait policy in patients with asymptomatic follicular lymphoma. While rituximab has improved treatment outcomes in follicular lymphoma patients, the appropriate timing, dosing and duration of therapy remain to be clarified in future clinical trials. Given the indolent nature of follicular lymphoma and the relatively long life expectancy associated with this disease, prognostic tools have an important role in guiding clinical decisions based on individual patient risk. © 2011 Hong Kong College of Radiologists.en_US
dc.languageengen_US
dc.publisherHong Kong Academy of Medicine Press. The Journal's web site is located at http://www.hkjr.orgen_US
dc.relation.ispartofHong Kong Journal of Radiologyen_US
dc.subjectLymphoma, Follicularen_US
dc.subjectRituximaben_US
dc.titleRituximab in the management of follicular lymphomaen_US
dc.typeArticleen_US
dc.identifier.emailKwong, YL:ylkwong@hku.hken_US
dc.identifier.authorityKwong, YL=rp00358en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.scopuseid_2-s2.0-84860266554en_US
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-84860266554&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume14en_US
dc.identifier.issue4 SUPPL.en_US
dc.identifier.spage63en_US
dc.identifier.epage67en_US
dc.publisher.placeHong Kongen_US
dc.identifier.scopusauthoridKwong, YL=7102818954en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats